192 results on '"Andrade, R.J."'
Search Results
2. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet
3. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry
4. P16-38: A systematic review of control compounds tested for validation of Drug-Induced Liver Injury (DILI) in vitro models
5. Incidence and predictors of hepatocellular carcinoma in autoimmune hepatitis: A multicenter international study
6. Hepatopatías de origen tóxico y farmacológico
7. Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
8. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation
9. Therapeutic management of idiosyncratic drug-induced liver injury and acetaminophen hepatotoxicity in the paediatric population: a systematic review
10. IDF21-0434 Distal symmetrical polyneuropathy: It’s (also) in your hands
11. Factores de riesgo y mecanismos de toxicidad hepática. Daño hepático inducido por medicamentos y tóxicos (excluido el alcohol)
12. Advancing the global public health agenda for NAFLD: a consensus statement
13. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
14. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old
15. Microbiota insights in clostridium difficile infection and inflammatory bowel disease
16. Clinical Characteristics and Outcome of Drug‐Induced Liver Injury in the Older Patients: From the Young‐Old to the Oldest‐Old
17. Case Report: Chronic Liver Injury Related to Use of Bentazepam
18. 2.26 - Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
19. Sciatic nerve stiffness is not changed immediately after a slump neurodynamics technique
20. Clinical Characteristics and Outcome of Drug‐Induced Liver Injury in the Older Patients: From the Young‐Old to the Oldest‐Old.
21. Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years
22. DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome
23. Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry
24. Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice
25. Independent cohort validation of hepatic metabolism, daily dose and comorbidities as features associated with delayed symptom onset in drug-induced liver injury
26. Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity
27. Genetic and functional analysis of FGF21 in NAFLD/NASH
28. Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
29. Expert clinical management of autoimmune hepatitis in the real world
30. The Influence of Drug Properties and Host Factors on Delayed Onset in Hepatotoxicity
31. Hepatitis E Virus, A Diagnosis to Consider in Drug Induced Liver Injury Assessment
32. Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure
33. Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD
34. Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice
35. Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals
36. Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry
37. Comparison of cytokine profiles in idiosyncratic drug-induced liver injury, acute non-drug-induced hepatitis and controls
38. Creating an effective clinical registry for rare diseases
39. Use of 18 F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue
40. Is Sensitivity the Key Measure to Predict Acute Liver Failure in Drug-Induced Liver Injury Patients?
41. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
42. Impact of Comorbidities and Polymedication in the Selection of Direct-Acting Antivirals in Patients with Chronic Hepatitis C in Spain
43. The Mechanisms Underlying Murine and Human Ibuprofen Intoxication
44. Pro-Euro-Dili Registry: A Collaborative Effort to Enhance the Understanding of Dili
45. Clinical Management of Autoimmune Hepatitis in the Real World
46. Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide fromthe Spanish and Latin-American Dili Registries
47. The FTO rs1421085 T > C Polymorphism is Associated with the Severity of Non-Alcoholic Fatty Liver
48. Impact of GWAS-Identified Common Variants on Histopathological Features of Non-Alcoholic Fatty Liver Disease Patients
49. SAT-507 - Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity
50. SAT-508 - Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.